Research programme: mitochondrial permeability transition pore inhibitors - MGI GPAlternative Names: GPI-19410
Latest Information Update: 20 Feb 2008
At a glance
- Originator MGI GP
- Class Small molecules
- Mechanism of Action Mitochondrial permeability transition pore inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Neurodegenerative disorders; Reperfusion injury
Most Recent Events
- 31 Dec 2007 Discontinued - Preclinical for Reperfusion injury in USA (unspecified route)
- 31 Dec 2007 Discontinued - Preclinical for Neurodegenerative disorders in USA (unspecified route)